title: Clinical Efficacy of Subgingivally Delivered 1.2 mg Simvastatin in the Treatment of Patients with Aggressive Periodontitis: A Randomized Controlled Clinical Trial.
abstract: Simvastatin (SMV) is a specific competitive inhibitor of 3-hydroxy-2-methylglutaryl coenzyme A reductase that promotes bone formation. The present clinical trial was designed to investigate the effectiveness of 1.2 mg SMV as a local drug delivery system and as an adjunct to scaling and root planing (SRP) in the treatment of aggressive periodontitis (AgP). A total of 68 intrabony defects from 24 patients with AgP were treated either with 1.2 mg SMV gel or placebo gel. The subjects were randomly assigned to SRP + placebo (group 1; n = 12) or SRP + SMV (group 2; n = 12). Clinical parameters were recorded at baseline and at 3 and 6 months and included bleeding index, Plaque Index, probing depth (PD), and clinical attachment level (CAL). At baseline and after 6 months, radiologic assessment of bone defect fill was done. The mean decrease in PD at 6 months was 1.14 ± 0.04 mm and 3.78 ± 0.62 mm in groups 1 and 2, respectively. Significant gain in mean CAL was found between the groups (P < .05). Furthermore, significantly greater mean percentage of bone fill was found in group 2 (34.01%) compared to group 1 (2.62%). Locally delivered SMV provides a comfortable method to improve clinical parameters and promotes bone formation.
authors.lastname: Priyanka N
authors.forename: A
authors.initials: A
authors.lastname: Abhilash
authors.forename: Shahab
authors.initials: S
authors.lastname: Saquib
authors.forename: Nikhil
authors.initials: N
authors.lastname: Malgaonkar
authors.forename: Nitin
authors.initials: N
authors.lastname: Kudyar
authors.forename: Aashima
authors.initials: A
authors.lastname: Gupta
authors.forename: Nitish
authors.initials: N
authors.lastname: Kalra
authors.forename: A R
authors.initials: AR
authors.lastname: Pradeep
mesh_terms: D000284:Administration, Oral; D000328:Adult; D010520:Aggressive Periodontitis / Q000188:drug therapy*; D016301:Alveolar Bone Loss / Q000145:classification / Q000188:drug therapy; D003131:Combined Modality Therapy; D003774:Dental Plaque Index; D012534:Dental Scaling / Q000379:methods; D005260:Female; D005782:Gels; D005888:Gingival Pocket / Q000188:drug therapy; D006801:Humans; D007194:India; D008297:Male; D008875:Middle Aged; D010012:Osteogenesis / Q000187:drug effects; D017622:Periodontal Attachment Loss / Q000145:classification / Q000188:drug therapy; D010512:Periodontal Index; D010514:Periodontal Pocket / Q000145:classification / Q000188:drug therapy; D010919:Placebos; D011861:Radiography, Dental; D016745:Root Planing / Q000379:methods; D019821:Simvastatin / Q000008:administration & dosage* / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D005782:Gels; D010919:Placebos; D019821:Simvastatin